PROTEA BIOSCIENCES GROUP, INC. (OTCMKTS:PRGB) Files An 8-K Regulation FD DisclosureItem 7.01
Protea Biosciences Group, Inc. (“PRGB” or the “Company”) intends to publish on its website and to furnish to investors an investor presentation dated September 2017 (the “Presentation”).A copy of the Presentation is furnished herewith as Exhibit 99.1.
The information furnished in this Item 7.01 and in Exhibit 99.1 of this Current Report on Form 8-K (this “Report”) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and such information shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
| Item 9.01. | Financial Statements and Exhibits |
(d) Exhibits
The following exhibit is filed with this Report:
| Exhibit No. | Description |
| 99.1 | Investor Presentation, dated September 2017. |
Protea Biosciences Group, Inc. ExhibitEX-99.1 2 v476204_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 A Revolution In Oncology Medicine 2 Molecular Information is the ultimate “big data” Trillions of cells in the human body continuously produce billions of biologically – active molecules that define our health and our disease Image of a tumor within a lung Source: PhRMA 2014 Industry Profile,…To view the full exhibit click here
About PROTEA BIOSCIENCES GROUP, INC. (OTCMKTS:PRGB)
Protea Biosciences Group, Inc. is a molecular information company. The Company is engaged in developing and commercializing life science technologies, products and services to identify the molecules that are produced by living cells and all life forms. It also offers a platform technology, Laser Ablation Electrospray Ionization (LAESI), which enables the direct analysis, mapping and display of molecular information in living cells and tissue samples. The Company’s commercial development is centered in three business lines: Molecular Information Services, LAESI Instruments, Software and Consumables, and Molecular Diagnostics and Clinical Research. Its services enable the identification and quantitation of both small molecules (lipids and metabolites) and large molecules (proteins) and the services portfolio, inclusive of mass spectrometry imaging (MSI), proteomics, metabolomics, lipidomics and bioinformatics. Its clients include pharmaceutical, chemical and biotechnology companies.
